#United States #Indianapolis #Diabetes Care #Eli Lilly #Foundayo

Lilly's Foundayo Shows Promise for Diabetes Management with Cardiovascular Benefits

Foundayo: A Breakthrough in Type 2 Diabetes Management

Eli Lilly and Company recently unveiled the impressive results from the Phase 3 ACHIEVE-4 trial for Foundayo (orforglipron), which is quickly gaining attention as a potential game-changer for type 2 diabetes treatment. This study, the largest and longest of its kind, compared Foundayo with titrated insulin glargine among adults with type 2 diabetes and obesity, who also face an elevated risk of cardiovascular events.

Key Findings from the ACHIEVE-4 Trial

The trial revealed that patients treated with Foundayo had a 16% lower risk of major adverse cardiovascular events (MACE-4) and a 23% lower risk of MACE-3 when compared to insulin glargine. This was critical in meeting the trial's primary objective of demonstrating non-inferiority in cardiovascular safety.

Interestingly, further analyses indicated a 53% reduction in cardiovascular death and a 57% reduction in all-cause mortality for patients on Foundayo, hinting at more comprehensive health benefits beyond just glycemic control. Dr. Klara Klein, from the University of North Carolina School of Medicine, emphasized that protecting heart health is equally as important as managing blood sugar levels for those living with type 2 diabetes.

Improvements in Key Health Metrics

Beyond heart health, participants taking Foundayo exhibited notable improvements across various cardiometabolic parameters by week 52. These included:

- A decrease in total waist circumference by 7.0 cm
- A drop in systolic blood pressure by 4.4 mmHg
- A reduction in triglycerides and non-HDL cholesterol by 18.9% and 6.6%, respectively
- A substantial 38.9% decrease in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation

Additionally, the drug was associated with a slower decline in kidney function when compared to insulin glargine, specifically showing less reduction in eGFR and lower albumin levels, which is significant given the correlation between kidney health and cardiovascular risk.

Comparative Efficacy

ACHIEVE-4 Results vs. Insulin Glargine

Metric	Foundayo	Insulin Glargine
--------	-----	----
Change in A1C from baseline (52 weeks)	-1.6%	-1.0%
Change in body weight	-8.8%	+1.7%
% achieving A1C ≤ 6.5%	54.6%	23.8%
% achieving weight reduction ≥10%	35.9%	3.4%

These statistics underscore how Foundayo is not only comparable to insulin glargine in terms of cardiovascular safety but also excels in efficacy for glycemic control and weight management.

Safety and Side Effects

The safety profile of Foundayo aligns closely with previous studies and other incretin medications, showing a manageable incidence of common side effects, which include nausea and gastrointestinal disturbances. Approximately 10.6% of patients discontinued treatment due to various adverse events, which is within the expected range for new medications in this class.

Dr. Thomas Seck from Eli Lilly highlighted the trial's outcomes, stating that more than half of participants managed to maintain an A1C of 6.5% or lower, marking sustainable results in blood sugar management and weight loss.

Future Directions

In an effort to further explore its impacts on cardiovascular outcomes, Eli Lilly is conducting the ATTAIN-OUTCOMES study, which focuses on patients with established cardiovascular or kidney disease. This continued research suggests a commitment from Lilly to fully understand the potential of Foundayo in improving patient health worldwide.

Conclusion

Overall, the results from the ACHIEVE-4 trial indicate that Foundayo could significantly influence how type 2 diabetes is treated globally, offering an innovative oral alternative that prioritizes both metabolic and cardiovascular health. With ongoing studies, patients and healthcare providers alike may soon find themselves with a powerful new ally in the battle against type 2 diabetes.